SGLT2 Inhibitors Reduce Atrial Fibrillation Progression In D
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Type 2 diabetes is closely related to an increased risk of atrial fibrillation (AF) and atrial flutter (AFL). Whether sodium-glucose cotransporter 2 (SGLT2) inhibitors can attenuate AF/AFL progression remains unclear.

The study included data from 16 identified trials consisting of 38,335 patients with type 2 diabetes.

Key findings include:
-- Incorporated data demonstrated that compared to placebo, SGLT2 inhibitors significantly reduced AF/AFL and all-cause mortality.
-- AF/AFL reductions were not modified by age, body weight, glycated haemoglobin (HbA1c), or systolic blood pressure (SBP) at baseline.
-- SGLT2 inhibitors also significantly reduced heart failure events, HbA1c, body weight, SBP, and diastolic blood pressure (DBP).
-- Of note, cerebrovascular events and myocardial infarction did not increase in patients taking SGLT2 inhibitors.

Conclusively, SGLT2 inhibitors may confer a specific AF/AFL-reduction benefit in the susceptible type 2 diabetes population, regardless of age, body weight, HbA1c, and systolic blood pressure at baseline. Such an AF/AFL-reduction benefit may be partly attributed to pharmacological effects on reductions in HbA1c, body weight, blood pressure, and the occurrence of heart failure.

Source: https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01105-5
Like
Comment
Share